Proton Therapy in an Era of Cost Containment

Restricted access

Dr. Herman received his medical degree from The University of Maryland and completed his residency at the University of Michigan Health System. In 2005, he joined the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University (JHU) in the Department of Radiation Oncology and Molecular Radiation Sciences where he is currently an associate professor.

Dr. Herman's clinical research interests focus on improving the quality and quantity of life of patients with gastrointestinal malignancies. He is currently the principal investigator of several clinical trials that combine radiation with chemotherapy, vaccine, and/or targeted agents for the treatment of patients with pancreatic and rectal cancer.

Dr. Herman developed and currently co-directs the pancreatic multidisciplinary clinic (MDC) at JHU. Over the past 4 years the clinic has evaluated more than 900 patients with pancreatic cancer.

Dr. Herman is a member of the NCCN Guidelines Panel for Pancreatic Cancer and the NCI's pancreatic and neuroendocrine cancer task force panels.

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.

  • 1

    Shaw E, Kline R, Gillin M. Radiation therapy oncology group: radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys 1993;27:12311239.

    • Search Google Scholar
    • Export Citation
  • 2

    Timmerman R, Bastasch M, Saha D. Optimizing dose and fractionation for stereotactic body radiation therapy. Normal tissue and tumor control effects with large dose per fraction. Front Radiat Ther Oncol 2007;40:352365.

    • Search Google Scholar
    • Export Citation
  • 3

    Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. Am J Clin Oncol 2007;30:637644.

  • 4

    Carlson RW. Industry ``rewrites'' of NCCN Guidelines. J Natl Compr Canc Netw 2011;9:257.

  • 5

    Welsh J, Gomez D, Palmer MB. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys, in press.

    • Search Google Scholar
    • Export Citation
  • 6

    Particle Therapy Co-Operative Group. Particle therapy facilities in operation (incl. patient statistics). Available at: http://ptcog.web.psi.ch/ptcentres.html. Accessed June 21, 2011.

    • Search Google Scholar
    • Export Citation
  • 7

    Chang JY, Komaki R, Lu C. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer, in press.

    • Search Google Scholar
    • Export Citation
  • 8

    Lee DW, Rawson JV, Wade SW. Radiology benefit managers: cost saving or cost shifting? J Am Coll Radiol 2011;8:393401.

  • 9

    Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol 2008;26:175176.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 67 57 1
PDF Downloads 13 8 0
EPUB Downloads 0 0 0